SCHEMBL22291341

SCHEMBL22291341

O=C(O)N1CC[C@H]1CNC(=O)C(F)(F)F

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.37
POLB P06746 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
CKS1B P61024 1/20 0.37
SKP1 P63208 1/20 0.37
SKP2 Q13309 1/20 0.37
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
PDK1 Q15118 1/20 0.35
PDK2 Q15119 1/20 0.35
PDK3 Q15120 1/20 0.35
PDK4 Q16654 1/20 0.35
CYP2D6 P10635 3/20 0.34
DPP4 P27487 3/20 0.34
DPP8 Q6V1X1 3/20 0.34
DPP9 Q86TI2 3/20 0.34
DPP7 Q9UHL4 3/20 0.34
CA2 P00918 2/20 0.33
CA3 P07451 2/20 0.33
CA5A P35218 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28793616 1.00 ALDH1A1 (0.37) ALDH1A1POLBSMN1; SMN2CKS1BSKP1
SCHEMBL9076510 0.90 DPP4 (0.42) ALDH1A1POLBSMN1; SMN2CKS1BSKP1
SCHEMBL8695534 0.90 DPP4 (0.42) ALDH1A1POLBSMN1; SMN2CKS1BSKP1
SCHEMBL22370514 0.89 HCRTR1 (0.39) CKS1BSKP1SKP2CYP2D6DPP4
SCHEMBL1598680 0.89 HCRTR1 (0.39) CKS1BSKP1SKP2CYP2D6DPP4
SCHEMBL1598683 0.89 HCRTR1 (0.39) CKS1BSKP1SKP2CYP2D6DPP4
SCHEMBL22318549 0.79 SMN1; SMN2 (0.41) ALDH1A1SMN1; SMN2CA14EPHX1OPRD1
SCHEMBL5783696 0.79 NQO2 (0.32) ALDH1A1POLBSMN1; SMN2CKS1BSKP1
SCHEMBL5783692 0.79 NQO2 (0.32) ALDH1A1POLBSMN1; SMN2CKS1BSKP1
SCHEMBL3104390 0.76 MTNR1A (0.34) ALDH1A1POLBSMN1; SMN2CKS1BSKP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240067642-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2024-02-29 US disclosed
US-20240002382-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2024-01-04 US disclosed
US-20230416246-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-12-28 US disclosed
US-20230331722-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-10-19 US disclosed
US-20230142883-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-05-11 US disclosed
US-20230077730-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2023-03-16 US disclosed
US-20230066136-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-03-02 US disclosed
US-11560381-B1 Compounds and uses thereof FOGHORN THERAPEUTICS INC. (US) 2023-01-24 US disclosed
US-11414416-B1 Compounds and uses thereof FOGHORN THERAPEUTICS INC. (US) 2022-08-16 US disclosed
CN-113874016-A Compound and use thereof 福宏治疗公司 2021-12-31 CN disclosed
EP-3917517-A1 COMPOUNDS AND USES THEREOF Foghorn Therapeutics Inc. (US) 2021-12-08 EP disclosed
EP-3917526-A1 COMPOUNDS AND USES THEREOF Foghorn Therapeutics Inc. (US) 2021-12-08 EP disclosed
WO-2020160192-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2020-08-06 WO disclosed
WO-2020160198-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2020-08-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230416246-A1 COMPOUNDS AND USES THEREOF VHL, TFEB, BECN1 ALDH1A1 1358/4885POLB 86/4885SMN1; SMN2 368/4885
US-20230066136-A1 COMPOUNDS AND USES THEREOF VHL, TFEB, BECN1 ALDH1A1 1358/4885POLB 86/4885SMN1; SMN2 368/4885
US-20230331722-A1 COMPOUNDS AND USES THEREOF VHL, TFEB, BECN1 ALDH1A1 1358/4885POLB 86/4885SMN1; SMN2 368/4885
US-20230077730-A1 COMPOUNDS AND USES THEREOF VHL, TFEB, BECN1 ALDH1A1 1387/4885POLB 90/4885SMN1; SMN2 360/4885
US-20240002382-A1 COMPOUNDS AND USES THEREOF VHL, TFEB, BECN1 ALDH1A1 1358/4885POLB 86/4885SMN1; SMN2 368/4885
US-20230142883-A1 COMPOUNDS AND USES THEREOF VHL, TFEB, BECN1 ALDH1A1 1358/4885POLB 86/4885SMN1; SMN2 368/4885
US-11414416-B1 Compounds and uses thereof VHL, TFEB, BECN1 ALDH1A1 1358/4885POLB 86/4885SMN1; SMN2 368/4885
US-11560381-B1 Compounds and uses thereof VHL, TFEB, BECN1 ALDH1A1 1358/4885POLB 86/4885SMN1; SMN2 368/4885
US-20240067642-A1 COMPOUNDS AND USES THEREOF VHL, TFEB, BECN1 ALDH1A1 1358/4885POLB 86/4885SMN1; SMN2 368/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.